Showing results (21-30 of 154) with videos related to
Sort By:
Pageof 16
F&S Reports|October 7, 2025
Outcomes of assisted reproductive technology after radical abdominal trachelectomy for early-stage cervical cancerShintaro Kamijo, Risa Matsuda, Mitsutoshi Yamada, et al.Gynecologic Oncology|August 29, 2021
Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint studyYasuhiko Ebina, Wataru Yamagami, Yoichi Kobayashi, et al.Japanese Journal of Clinical Oncology|September 4, 2013
Hypertriglyceridemia is frequent in endometrial cancer survivorsAkira Hirasawa, Kazuya Makita, Tomoko Akahane, et al.Gynecologic Oncology|October 23, 2025
Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancerHiroko Machida, Kei Kawana, Aikou Okamoto, et al.Journal of Gynecologic Oncology|May 12, 2025
Characteristics of endometrial cancer progressed to extrauterine lesions following fertility preserving medroxyprogesterone acetate therapy for young endometrial cancer patientsShoko Kitazawa, Kensuke Sakai, Miho Kawaida, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesisNoritoshi Kobayashi, Nobuyoshi Hiraoka, Wataru Yamagami, et al.Journal of Gynecologic Oncology|May 24, 2024
A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial)Kensuke Sakai, Wataru Yamagami, Yasunori Sato, et al.Archives of Pathology & Laboratory Medicine|October 13, 2024
Advancing Precision Oncology: Whole-Exome Sequencing in Endometrial Cancer Liquid-Based CytologyReika Takamatsu, Kohei Nakamura, Tatsuyuki Chiyoda, et al.Journal of Gynecologic Oncology|February 6, 2018
Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?Wataru Yamagami, Nobuyuki Susumu, Takeshi Makabe, et al.Japanese Journal of Clinical Oncology|February 1, 2005
Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in JapanYoshiko Kuwabara, Nobuyuki Susumu, Kouji Banno, et al.Pageof 16